GlassScriptPhysician profile
Melissa Spring Redding
NPI 1831588623
$5,249.26
in general payments reported to CMS, 2019-2025
27 companies · $566 in 2025
The $566 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,363 · 2022: $1,166 · 2023: $622 · 2024: $1,533 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,720.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $878.68 | 2021-2025 | Farxiga, Lokelma |
| Amgen INC. | $556.86 | 2021-2025 | Krystexxa, Tavneos, Parsabiv |
| Bayer Healthcare Pharmaceuticals INC. | $487.48 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $429.49 | 2021-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $281.24 | 2021-2024 | Rayaldee |
| Fresenius USA Marketing, INC. | $256.44 | 2021-2023 | Velphoro |
| Daiichi Sankyo INC. | $236.92 | 2021-2025 | Injectafer |
| Veloxis Pharmaceuticals, INC. | $210.90 | 2021-2024 | Envarsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.86 | 2023-2025 | Jardiance |
| Vifor Pharma, INC. | $207.69 | 2021-2023 | Veltassa |
| Horizon Therapeutics Plc | $197.08 | 2022-2023 | Krystexxa |
| Pharmacosmos Therapeutics INC. | $188.48 | 2021-2025 | Monoferric |
| Travere Therapeutics, INC. | $155.44 | 2022-2025 | Filspari |
| Aurinia Pharma U.S., INC. | $153.13 | 2021-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $130.73 | 2022-2025 | Tarpeyo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $99.09 | 2022-2024 | Ultomiris |
| Ardelyx, INC. | $85.49 | 2023-2025 | Ibsrela |
| Ani Pharmaceuticals, INC. | $75.68 | 2022-2025 | Purified Cortrophin Gel |
| Novo Nordisk INC | $75.37 | 2021-2025 | Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $65.53 | 2021-2023 | Gattex |
| Akebia Therapeutics INC | $62.82 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $55.38 | 2021-2022 | |
| Glaxosmithkline, LLC. | $39.91 | 2021-2022 | |
| Cormedix INC. | $36.15 | 2024 | Defencath |
| Ultragenyx Pharmaceutical INC. | $34.95 | 2021-2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.12 | 2021 | |
| Amag Pharmaceuticals, INC. | $15.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Redding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.